These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3163399)

  • 1. Alpha-interferon in myelodysplasia; clinical observations and effects on NK cells.
    Galvani DW; Nethersell AB; Cawley JC
    Leuk Res; 1988; 12(3):257-62. PubMed ID: 3163399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.
    Fontana L; De Sanctis G; De Rossi G; Bottari V; Petti MC; Ensoli F; Pasqualetti D; Mandelli F
    Acta Haematol; 1989; 82(1):1-6. PubMed ID: 2505468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of recombinant human interferon alpha in myelodysplastic syndromes.
    Nand S; Ellis T; Messmore H; Fisher SG; Gaynor E; Fisher RI
    Leukemia; 1992 Mar; 6(3):220-3. PubMed ID: 1564960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b.
    Aul C; Gattermann N; Schneider W
    Eur J Haematol; 1991 Jan; 46(1):11-6. PubMed ID: 1988303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms accounting for the impaired natural-killer cell activity in refractory anaemia with excess of blasts.
    Eliopoulos GD; Coulocheri SA; Eliopoulos AG; Katrinakis G; Karkavitsas N; Kyriakou D; Vaiopoulos G; Foudoulakis A
    Eur J Haematol; 1992 May; 48(5):237-43. PubMed ID: 1379537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes.
    Ogata K; Tamura H; Yokose N; An E; Dan K; Hamaguchi H; Sakamaki H; Onozawa Y; Clark SC; Nomura T
    Br J Haematol; 1995 May; 90(1):15-21. PubMed ID: 7786778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired alpha-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes.
    Okabe M; Minagawa T; Nakane A; Sakurada K; Miyazaki T
    Scand J Haematol; 1986 Aug; 37(2):111-7. PubMed ID: 3489981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
    Wimazal F; Krauth MT; Vales A; Böhm A; Agis H; Sonneck K; Aichberger KJ; Mayerhofer M; Simonitsch-Klupp I; Müllauer L; Sperr WR; Valent P
    Leuk Lymphoma; 2006 Mar; 47(3):451-60. PubMed ID: 16396768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotyping of blasts in refractory anaemia with excess of blasts.
    Oertel J; Kleiner S; Huhn D
    Br J Haematol; 1993 Jun; 84(2):305-9. PubMed ID: 7691147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
    Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
    J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
    Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The beneficial effects of alpha IFN in CGL are probably not mediated by NK cells.
    Galvani DW; Owens W; Nethersell AB; Cawley JC
    Br J Haematol; 1989 Feb; 71(2):233-7. PubMed ID: 2923809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
    Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
    Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of therapy-related myelodysplasia to low-dose interleukin-2.
    Toze CL; Barnett MJ; Klingemann HG
    Leukemia; 1993 Mar; 7(3):463-5. PubMed ID: 8445951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
    Griffiths SD; Cawley JC
    Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
    Ogata K; Yokose N; Nomura T
    Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial of recombinant alpha 2 interferon in the myelodysplastic syndromes: I. Clinical results.
    Elias L; Hoffman R; Boswell S; Tensen L; Bonnem EM
    Leukemia; 1987 Feb; 1(2):105-10. PubMed ID: 3478534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score.
    Oscier DG; Worsley A; Darlow S; Figes A; Williams JD; Hamblin TJ
    Leuk Res; 1989; 13(9):833-9. PubMed ID: 2796388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification.
    Vallespi T; Torrabadella M; Julia A; Irriguible D; Jaen A; Acebedo G; Triginer J
    Br J Haematol; 1985 Sep; 61(1):83-92. PubMed ID: 3863667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD 34 immunotyping of blasts in myelodysplasia.
    Oertel J; Oertel B; Beyer J; Huhn D
    Ann Hematol; 1994 Feb; 68(2):77-80. PubMed ID: 7511934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.